Deere & Company (DE)
NYSE: DE · Real-Time Price · USD
500.98
-23.39 (-4.46%)
At close: Aug 1, 2025, 4:00 PM
501.99
+1.01 (0.20%)
After-hours: Aug 1, 2025, 7:51 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $515.87, which forecasts a 2.97% increase in the stock price over the next year. The lowest target is $389 and the highest is $619.
Price Target: $515.87 (+2.97%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 9 | 10 | 10 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 17 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $555 → $560 | Buy | Maintains | $555 → $560 | +11.78% | Jul 15, 2025 |
| Citigroup | Citigroup | Hold Maintains $550 → $525 | Hold | Maintains | $550 → $525 | +4.79% | May 30, 2025 |
| BMO Capital | BMO Capital | Hold Maintains $425 → $460 | Hold | Maintains | $425 → $460 | -8.18% | May 21, 2025 |
| Citigroup | Citigroup | Hold Maintains $450 → $550 | Hold | Maintains | $450 → $550 | +9.78% | May 19, 2025 |
| Evercore ISI Group | Evercore ISI Group | Hold Maintains $455 → $493 | Hold | Maintains | $455 → $493 | -1.59% | May 19, 2025 |
Financial Forecast
Revenue This Year
39.28B
from 51.53B
Decreased by -23.78%
Revenue Next Year
42.06B
from 39.28B
Increased by 7.09%
EPS This Year
19.34
from 25.62
Decreased by -24.53%
EPS Next Year
23.12
from 19.34
Increased by 19.58%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 40.8B | 46.2B | 49.7B |
| Avg | 39.3B | 42.1B | 45.4B |
| Low | 36.5B | 36.5B | 39.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -20.9% | 17.5% | 18.1% |
| Avg | -23.8% | 7.1% | 8.0% |
| Low | -29.1% | -7.2% | -5.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.48 | 29.64 | 38.82 | ||
| Avg | 19.34 | 23.12 | 27.90 | ||
| Low | 17.64 | 18.68 | 22.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -20.1% | 53.3% | 67.9% | ||
| Avg | -24.5% | 19.6% | 20.7% | ||
| Low | -31.1% | -3.4% | -4.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.